Mubucho (Dasatinib)

Dasatinib inhibits the ATP‑binding sites of BCR‑ABL and Src family tyrosine kinases. By blocking these enzymes, it stops downstream signaling that promotes malignant cell growth, survival, and migration, leading to apoptosis of leukemic cells and clinical disease control.

The dose of dasatinib is individualized by the prescribing clinician based on the specific indication, disease phase, patient weight, renal and hepatic function, and concomitant therapies. Only a qualified health‑care professional should determine the appropriate regimen.

Safety data for dasatinib in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it is generally avoided unless the potential therapeutic benefit outweighs the possible risk to the fetus. Breastfeeding is not recommended while receiving treatment.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to dasatinib is imatinib, a first‑generation BCR‑ABL inhibitor. Dasatinib has a broader kinase inhibition profile, including Src family kinases, and often achieves faster and deeper molecular responses, especially in patients resistant or intolerant to imatinib. Choice of therapy depends on individual patient factors and physician judgment.

Mubucho should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and avoid exposure to high humidity or extreme temperatures.

Mubucho is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent absorption.

The most serious adverse events include pulmonary arterial hypertension, severe bleeding, and cardiac dysfunction such as left‑ventricular failure. Patients should promptly report symptoms like shortness of breath, chest pain, unexplained bruising or bleeding, and swelling of the legs or ankles.

Mubucho is contraindicated in patients with known hypersensitivity to dasatinib or any of its excipients. It should be used with caution in individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding unless the benefit clearly outweighs the risk.